ACE2: A new target for prevention of diabetic nephropathy?

Journal of the American Society of Nephrology

Volumn 17, Issue 11, 2006, Pages 2957-2959

  Ingelfinger, Julie R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-9]; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MLN 4760; TELMISARTAN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BOWMAN MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EDITORIAL; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FEMALE; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEQUENCE HOMOLOGY; STREPTOZOCIN DIABETES;

EID: 33750721682     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006090986     Document Type: Editorial

References (18)

1. Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993;
3. published erratum in: N Engl J Med 330: 152, 1993
4. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000
5. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000
6. Sarkissian SD, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK: ACE2: A novel therapeutic target for cardiovascular diseases. Progr Biophys Molec Biol 91: 163-198, 2006
7. Turner AJ, Tipnes SR, Guy JL, Rice G, Hooper NM: ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80: 246-353, 2002
8. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical and molecular biological correlations. Am J Physiol 265: F477-F486, 1993
9. Singh R, Singh AK, Leehey DJ: A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 288: 1183-1190, 2005
10. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME: Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2000
11. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D: ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139, 2006
12. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D: Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075, 2006
13. Wagner J, Gehlen F, Ciechanowicz A, Ritz E: Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 10: 545-551, 1999
14. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10: 2382-2391,1999
15. Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, Kawai Y, Kato N, Koni I, Miyamori I, Mabuchi H: Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 29: 848-852, 2006
16. Frojdo S, Sjolind L, Parkkonen M, Makinen VP, Kilpikari R, Pettersson-Fernholm K, Forsblom C, Fagerudd J, Tikellis C, Cooper ME, Wessman M, Groop PH; FinnDiane Study Group: Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. Diabetologia 48: 2278-2281, 2005
17. Su Z, Zimpelmann J, Burns KD: Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218, 2006
18. Katovich MJ, Grobe JL, Huentelman M, Raizada MK: Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp Physiol 90: 299-305, 2005